REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will ...
Pharmabiz16d
REGENXBIO & Nippon Shinyaku enter exclusive partnership to develop and commercialize RGX-121 and RGX-111 for MPS diseases
REGENXBIO Inc., a leading clinical-stage biotechnology company, and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced a strategic partnership for the development and commercialization of RGX-121 ...